Titration to target dose of bisoprolol vs. carvedilol in elderly patients with heart failure: the CIBIS-ELD trial. - Wikidata - wikimedia - TriplyDB

Titration to target dose of bisoprolol vs. carvedilol in elderly patients with heart failure: the CIBIS-ELD trial.

Titration to target dose of bisoprolol vs. carvedilol in elderly patients with heart failure: the CIBIS-ELD trial.

http://www.wikidata.org/entity/Q35006600

about

Effect of β-blockers on cardiac and pulmonary events and death in older adults with cardiovascular disease and chronic obstructive pulmonary disease.Optimized treatment and heart rate reduction in chronic heart failure.Heart failure in elderly patients: distinctive features and unresolved issues.Potential drug-drug interactions in hospitalized patients with chronic heart failure and chronic obstructive pulmonary disease Noncardiac comorbidities in heart failure with reduced versus preserved ejection fraction Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy.In Silico comparison between metoprolol succinate and bisoprolol on 24-hour systolic blood pressures Potential therapeutic competition in community-living older adults in the U.S.: use of medications that may adversely affect a coexisting condition.Impact of β-blocker selectivity on long-term outcomes in congestive heart failure patients with chronic obstructive pulmonary disease Relationship of beta-blocker dose with outcomes in ambulatory heart failure patients with systolic dysfunction: results from the HF-ACTION (Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training) trial.Heart failure in elderly: progress in clinical evaluation and therapeutic approach.In-hospital cardiology consultation and evidence-based care for nursing home residents with heart failure.Chronic heart failure: we are fighting the battle, but are we winning the war?Noncardiac comorbidities and acute heart failure patients.Heart rate achieved or beta-blocker dose in patients with chronic heart failure: which is the better target?Heart failure and chronic obstructive pulmonary disease: the challenges facing physicians and health services.β-Blockers and chronic obstructive pulmonary disease: inappropriate avoidance?Chronic obstructive pulmonary disease in heart failure: accurate diagnosis and treatment.Regional differences in health-related quality of life in elderly heart failure patients: results from the CIBIS-ELD trial.Obstructive Ventilatory Disorder in Heart Failure-Caused by the Heart or the Lung?Heart failure management in the elderly - a public health challenge.This patient is not breathing properly: is this COPD, heart failure, or neither?Optimization of heart failure medication after cardiac resynchronization therapy and the impact on long-term survival.Determinants and clinical outcome of uptitration of ACE-inhibitors and beta-blockers in patients with heart failure: a prospective European study.Poor self-rated health predicts mortality in patients with stable chronic heart failure.[Competence Network Heart Failure (CNHF). Together against heart failure].COPD in heart failure: are there long-term implications following acute heart failure hospitalization?Should we revise our approach to 'optimal medical therapy'? The case of chronic heart failure.Beta blocker dose and markers of sympathetic activation in heart failure patients: interrelationships and prognostic significance.Cardiopulmonary interactions with beta-blockers and inhaled therapy in COPD.Potentially inappropriate drug prescribing in elderly hospitalized patients: an analysis and comparison of explicit criteria.Left cardiac sympathetic denervation for treatment of symptomatic systolic heart failure patients: a pilot study.Effects of the long-term administration of nebivolol on the clinical symptoms, exercise capacity, and left ventricular function of patients with diastolic dysfunction: results of the ELANDD study.Beneficial Effect on Surrogate Markers of Heart Failure with Bisoprolol Up-Titration to Recommended Targets in Korean Patients with Heart Failure and Left Ventricular Systolic Dysfunction.Insufficient reduction in heart rate during hospitalization despite beta-blocker treatment in acute decompensated heart failure: insights from the ASCEND-HF trial.Clinical tolerability of generic versus brand beta blockers in heart failure with reduced left ventricular ejection fraction: a retrospective cohort from heart failure clinic.Relationship between heart failure, concurrent chronic obstructive pulmonary disease and beta-blocker use: a Danish nationwide cohort study.Drug treatment of heart failure in the elderly.Addition of ivabradine to β-blocker improves exercise capacity in systolic heart failure patients in a prospective, open-label study.Heart rate following short-term beta-blocker titration predicts all-cause mortality in elderly chronic heart failure patients: insights from the CIBIS-ELD trial

P2860

Q33730879-562D5132-30EA-4A62-8B43-FCE0CCE58790 Q33843442-E18FB92C-1379-4A15-B224-2D25C8A09E17 Q34248538-8E98BD7C-E2D2-46C2-9357-D452A8DB5173 Q34466749-BDAF3F2F-5357-4137-AB56-96FB52DFFE6B Q34625223-56986E65-80A7-44E2-86BD-0CD4164743D3 Q34631911-AEC888AD-56D0-4199-9950-4AC82915146A Q34727832-7FCDEA3A-A31F-4E86-8972-9AE0E6C908C3 Q35107345-300FAFE9-3819-4F58-AB47-03DAFD0DCAFA Q35168749-39A9693B-A367-4F10-AE52-903848D9092B Q36094884-A2469878-DC50-41AE-B509-C2236D4425F0 Q37001576-DFE124CD-ADCB-4FBB-8FA2-B66199A5B417 Q37112577-B38C83C7-37F2-44BF-B7B8-8FA1F7E08CB1 Q37288386-A6C239A2-6B6E-40D3-97C8-C2E2B68A21C2 Q37531314-98502F41-6388-4A45-9325-E272E69102E8 Q38012561-68ABB072-D511-45A7-8359-A5AD00CCD5AA Q38119867-4535E34A-3B40-46C1-BDC5-9556CE9B3D08 Q38150473-CF0A769D-82FB-4F4F-9375-881BC656017F Q38262835-A222FC83-7C2F-42F5-83F5-BE89B1205F60 Q38737378-A918655B-D13B-43E6-9E47-5990055BEC6B Q39000103-50027D34-CB50-4A52-BEB8-C503144A70CC Q39024144-31070DCB-85B3-4509-9117-C5A6A30FA564 Q39232408-A8CCD7B6-18C4-4A00-A4C6-BAE3F3589AF5 Q39481491-84AF9DBF-E86D-429A-A929-CD952E8869F4 Q40280356-E942DCE5-A4C6-46BF-A5F1-6B9A291A7D89 Q40359662-E2B71037-2BF2-4CB8-A886-51EDAC83BDC3 Q40852329-4DE5E1F4-C99C-41A0-9727-D2E548C9C122 Q43056249-F51C4A0E-95FC-4056-983E-C9F1D9551428 Q43722663-453EDDC5-4BA8-4FF5-B919-7DBB82208B52 Q47677541-3E1C1D82-FE8D-4B57-899D-D2C0A475C281 Q47746323-D72B5336-8772-477B-A4A3-EF53B5D202EE Q47854986-D4D6ABCD-06B5-4421-BA72-252E92FC85C2 Q48320544-4B8F8C88-0E72-4D26-85FE-36C16843542E Q48795012-79CCB63A-46A6-44D3-A3F4-9E15DB2748D0 Q48818918-85243C4F-2C76-45CA-BD3E-1D8B65DA8FB2 Q49044088-45C97C1F-F7D7-47A8-9BAF-F4008A424A7A Q49591511-50779C29-058C-4C6D-8E82-AB979B3118AE Q49841575-61A46BD8-053F-4FE4-BDD2-F90CA236BE24 Q50014420-6E4D8B67-BB39-4D76-8429-AAA149BFD9CD Q51006365-C5ADC801-29D9-427A-8C83-C1FABE0EFBC5 Q56958327-943A04BA-F4C4-4820-BC2B-66B909452714

P2860

Titration to target dose of bisoprolol vs. carvedilol in elderly patients with heart failure: the CIBIS-ELD trial.

http://www.wikidata.org/entity/Q35006600

description

2011 nî lūn-bûn

@nan

2011 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի մարտին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年学术文章

@wuu

2011年学术文章

@zh-cn

2011年学术文章

@zh-hans

2011年学术文章

@zh-my

2011年学术文章

@zh-sg

2011年學術文章

@yue

name

Titration to target dose of bi ...... failure: the CIBIS-ELD trial.

@ast

Titration to target dose of bi ...... failure: the CIBIS-ELD trial.

@en

type

label

Titration to target dose of bi ...... failure: the CIBIS-ELD trial.

@ast

Titration to target dose of bi ...... failure: the CIBIS-ELD trial.

@en

prefLabel

Titration to target dose of bi ...... failure: the CIBIS-ELD trial.

@ast

Titration to target dose of bi ...... failure: the CIBIS-ELD trial.

@en

P1433

Q35006600-8FE7FEDE-6C73-4A62-9FB4-E63CF08ECB7A

P1476

Q35006600-EC2FCF96-9BC7-48D2-B08C-01079CEE12ED

P2093

Q35006600-0152B629-ED8D-4B3E-AD8C-53D68D85E5C2

Q35006600-0DD5F98B-32C6-4F76-94C9-121FF3F15CE9

Q35006600-1A8946D0-8927-4B0E-9B02-62769B0B3E65

Q35006600-1B8F86A8-73B7-48FA-B2D6-8473CAC7E928

Q35006600-51E19BF6-71D5-4731-AAC9-7A8D6EA7D335

Q35006600-58C95295-D39A-4EFC-86F8-7A58DD87853A

Q35006600-5AD3656A-2281-4A43-AB52-79EF07DCB4CF

Q35006600-682BD57A-A214-4E2B-8707-ED2A5720A0E5

Q35006600-69400AB3-2C4C-4C95-A62D-AD5887B2D14D

Q35006600-775E6056-5854-4F4F-88BA-65BE32AD2FD4

P2860

Q35006600-0CA58D53-F115-461E-8243-B0948DFDC72F

Q35006600-0CFA614D-25B1-42B4-9B03-2BC7AFB5459F

Q35006600-0DF714D0-0005-4CF8-BB40-FCE3CD1E4A7E

Q35006600-112CE6DD-8FBD-4119-AF11-780F0C8F4EF2

Q35006600-16736122-6063-46DA-AD47-40781E010149

Q35006600-1B6040A5-1332-4653-BDEF-AEF279EDB370

Q35006600-3BAD182C-32FB-4D38-9CD4-5D5EE841FAEE

Q35006600-3C21949B-3257-4049-95BE-C56892BBA8D6

Q35006600-51265E0A-9B5C-4B13-8212-580DF76D26A3

Q35006600-5C5AE921-CEB5-4245-8307-E9661049B808

P304

Q35006600-51A6A015-758E-48E9-BD89-A268D4C41F4D

P31

Q35006600-EEE313CA-9E0C-4821-84BC-E09193145BAB

P356

Q35006600-C544CD97-8A0E-4790-9B6A-259B31C85277

P433

Q35006600-BB703CAA-06DE-4C7B-8419-440BA3DD140E

P478

Q35006600-53B24AC1-85DF-4B97-898E-74A706637E7E

P50

Q35006600-18210F9B-F62B-4255-BC56-D4A4BC0BEF45

Q35006600-2387DC49-7E36-4D61-A7DA-6FBEA4CDFA8F

Q35006600-682333F4-0D74-49A7-BADA-8546A57DC2EF

Q35006600-9B623960-3EE6-4F80-965C-A11F39A26BE6

Q35006600-9D913B21-E938-4135-97CF-F4FFC18A3F10

P577

Q35006600-9AAA2F3C-9138-48C0-850E-BD205310756E

P5875

Q35006600-53533ED5-07C4-4278-8B7C-CEB5260810D5

P698

Q35006600-9F8531BE-F8F1-4B2B-A65F-AA444B56A2F7

P921

Q35006600-D50240DE-3D7A-4C0F-857B-24C826B96E49

Q35006600-F2CB8324-A0C2-4FE0-A957-E676057EF9BE

P932

Q35006600-ACFA94B8-9EC6-453F-8A37-FCA1A853D5A9

P356

P1433

European Journal of Heart Failure

P1476

Titration to target dose of bi ...... failure: the CIBIS-ELD trial.

@en

P2093

Agnieszka Töpper

http://www.w3.org/2001/XMLSchema#string

Biljana Putnikovic

http://www.w3.org/2001/XMLSchema#string

CIBIS-ELD investigators and Pr ...... mpetence Network Heart Failure

http://www.w3.org/2001/XMLSchema#string

Christiane Prettin

http://www.w3.org/2001/XMLSchema#string

Dejan Sakac

http://www.w3.org/2001/XMLSchema#string

Elvis Tahirovic

http://www.w3.org/2001/XMLSchema#string

Felix Mehrhof

http://www.w3.org/2001/XMLSchema#string

Finn Waagstein

http://www.w3.org/2001/XMLSchema#string

Frank Edelmann

http://www.w3.org/2001/XMLSchema#string

Goetz Gelbrich

http://www.w3.org/2001/XMLSchema#string

P2860

The EuroHeart Failure Survey programme--a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment

2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: de

Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)

Tolerability and dose-related effects of nebivolol in elderly patients with heart failure: data from the Study of the Effects of Nebivolol Intervention on Outcomes and Rehospitalisation in Seniors with Heart Failure (SENIORS) trial.

Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: Data From SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Fail

Epidemiology, aetiology, and prognosis of heart failure.

Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study.

Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial.

Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS).

The EuroHeart Failure survey programme-- a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis.

P304

670-680

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/EURJHF/HFR020

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

13

http://www.w3.org/2001/XMLSchema#string

P50

Stefan D. Anker

Christoph Herrmann-Lingen

Aleksandar N Neskovic

P577

2011-03-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

50831380

http://www.w3.org/2001/XMLSchema#string

P698

21429992

http://www.w3.org/2001/XMLSchema#string

P921

P932

3101867

http://www.w3.org/2001/XMLSchema#string